Investigating the direct detection of sepsis causing bacteria from whole human blood.

该项目调查了直接从人类血液中检测细菌感染（导致败血症）的可行性。该过程包括通过快速循环冷冻和煮沸裂解细菌细胞，然后通过实时PCR检测释放的核酸。与目前使用的广谱抗生素治疗相比，这种新方法将能够在怀疑败血症后的关键1小时内检测细菌感染，从而更有针对性和更适当地使用抗生素。如果临床医生有数据概述哪些细菌存在，重要的是哪些抗生素可能是最合适的，那么英国每年超过15万例细菌性败血症的结果将大大改善，并减少每年4万例可归因为这种情况的死亡率。BGR已经证明，该技术及其仪器QuRapID能够检测血液传播疾病，如埃博拉病毒、寨卡病毒和疟疾。该项目将测试受感染的血液，以确定该技术的好处是否可以应用于败血症，其中细菌细胞的数量远低于病毒性疾病。BGR将获得来自受感染患者的血液，以便在小规模上与NHS医院使用的现有金标准方法进行比较。

The project investigates the feasibility of detecting bacterial infections, causing sepsis, directly from whole human blood. The process involves lysing the bacterial cells by rapid cyclical freezing and boiling followed by detection of the released nucleic acid by real-time PCR. This novel approach will enable detection of bacterial infection in the critical ,1hr period after sepsis is suspected, leading to more targeted and appropriate use of antibiotics in contrast to the broad-spectrum antibiotic treatment used currently. If the clinician has data outlining which bacteria are present and importantly which antibiotics are likely to be most suitable, then the outcome for the more than 150k annual UK cases of bacterial sepsis will be greatly improved and reduce the 40k annual mortalities attributable to this condition. BGR has demonstrated that the technique and it's instrumentation, the QuRapID, is able to detect blood borne diseases such as Ebola, Zika and Malaria. This project will test infected blood in order to find out if the benefits of the technique can be applied to sepsis, where the number of bacterial cells is much lower than in viral disease. BGR will have access to blood from infected patients to compare on a small scale to existing gold standard methods in use by an NHS hospital.